A HIGHER INDUCTION DOSING REGIMEN OF ADALIMUMAB DOES NOT ENHANCE MODULATION OF DOWNSTREAM BLOOD MOLECULAR MARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE OR ULCERATIVE COLITIS: RESULTS FROM THE SERENE-CD AND SERENE-UC STUDIES

Marc Ferrante  ¹     Valerie Pivorunas  ²     James Butler  ³     Naim Mahi  ³     Nael M. Mostafa  ³     Melanie Ruzek  ³     James Fann  ³     Feng Hong  ³     Xiaohong Cao  ⁴     Nizar Smaoui  ⁴     Justin Wade Davis  ⁴     Jasmina Kalabic  ⁵     Alexandra Song  ⁵     Heath M. Guay  ⁵     Florian Rieder  ⁶     Julian Panés  ⁷     Jean-Frédéric Colombel  ^8    
1 University Hospitals Leuven, KU Leuven, Belgium
² AbbVie Bioresearch Center, Worcester, United States
³ AbbVie Inc., North Chicago, United States
⁴ AbbVie Cambridge Research Center, Cambridge, United States
⁵ AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
⁶ Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, United States
⁷ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁸ Icahn School of Medicine at Mt. Sinai, New York, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)